Physician profile
Joyce Garrison
NPI 1992585749
$2,233.40
in general payments reported to CMS, 2019-2025
18 companies · $1,274 in 2025
The $1,274 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $153 · 2024: $806 · 2025: $1,274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,233.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $391.94 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $352.73 | 2024-2025 | |
| Lilly USA, LLC | $313.68 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $263.59 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $198.58 | 2025 | Repatha, Otezla, Prolia |
| Dexcom, INC. | $183.74 | 2024-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Exact Sciences Corporation | $113.65 | 2024-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $74.31 | 2024-2025 | Korlym |
| Astellas Pharma US INC | $60.06 | 2025 | Veozah |
| Axsome Therapeutics, INC. | $51.96 | 2025 | Symbravo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.99 | 2025 | Jascayd |
| Glaxosmithkline, LLC. | $38.58 | 2024-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Sumitomo Pharma America, INC. | $37.02 | 2025 | Myfembree, Gemtesa |
| Baxter Healthcare | $32.58 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Pfizer INC. | $29.78 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $21.22 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $16.03 | 2025 | Zoryve |
| Medtronic, INC. | $14.96 | 2024 | Intellis Adaptivestim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joyce Garrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.